Phase 1
Recruiting
Locally Advanced
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07265028 as a single agent and in combination with sasanlimab, Anti-pro…